Gimv has completed its investment in Germany's Apraxon Group, a leading homecare company specializing in wound care. This deal is part of a joint growth strategy with the company's founder and CEO, Oliver Pokrzewinski, who will remain a significant shareholder.
Apraxon provides high-quality wound care in a homecare environment for (mostly elderly) people with chronic wounds. Decubitus, diabetic foot, and ulcus cruris are common wound indications. The business serves as a middleman for patients, physicians, nursing homes, and insurance firms in delivering this service.
Apraxon consistently offers high-quality medical services and is able to customize the treatment process to each patient's specific needs thanks to its high level of expertise. Specialized medical care is becoming more important in a market of steadily growing patient numbers, largely due to demographic change. Health insurance firms reimburse Apraxon's services, and Apraxon has been a trusted partner for them for many years.
"I am convinced that Gimv is the right partner to realize the company’s growth ambitions and expand Apraxon’s footprint in Germany," explains Oliver Pokrzewinski, Managing Director and CEO of Apraxon.
“Thanks to Apraxon’s clear commitment to quality, highly qualified nursing staff and strongly digitised and scalable processes, we believe that Apraxon is the right platform to build a true leader in the German wound care market. We are very much looking forward to supporting Mr. Pokrzewinski and the entire Apraxon team in realising their ambitious growth plans," says Philipp v. Hammerstein, Partner at Gimv in the Health & Care team in Munich.
Over the last four years, Gimv has made five acquisitions in the German-speaking healthcare industry. Currently, Gimv has 23 participations in healthcare and life sciences firms. This acquisition solidifies Gimv's status as one of Europe's most successful healthcare investors, as well as its desire to contribute positively to the United Nations Sustainable Development Goals of good health and well-being. Several clinic and practice associations, as well as medical technology and pharmaceutical firms, are part of the Gimv portfolio.
